首页> 外文期刊>Journal of Thoracic Disease >Phenotypic and genotypic characterization of levofloxacin- and moxifloxacin-resistant Mycobacterium tuberculosis clinical isolates in southern China
【24h】

Phenotypic and genotypic characterization of levofloxacin- and moxifloxacin-resistant Mycobacterium tuberculosis clinical isolates in southern China

机译:南方南方左氧氟沙星 - 耐甲氧辛辛和静脉曲菌结核分枝杆菌临床分离株的表型和基因型表征

获取原文
获取外文期刊封面目录资料

摘要

Background: Levofloxacin (LVX) and Moxifloxacin (MXF) are the cornerstones for treatment of multidrug-resistant tuberculosis (MDR-TB). China is one of the highest MDR- and fluoroquinolones (FQ)- resistant TB burdens countries. DNA gyrase encoded by gyr genes is the main target of FQ in Mycobacterium tuberculosis (MTB). The prevalence and molecular characterization of LVX- and MXF-resistant MTB strains from southern China were examined in this study. Methods: Drug susceptibility testing (DST) of 400 MTB clinical isolates was evaluated by proportion method on L?wenstein-Jensen (LJ) medium against ten drugs. The sequencing of entire gyrA and gyrB genes and multiplex PCR were performed to distinguish the prevalence of mutant types in Beijing and non-Beijing genotypes. Results: Three hundred and twenty-one out of four hundred (80.25%) drug-resistant isolates (resistant one drug) were categorized as 83/321 (25.80%) MDR, 174/321 (54.20%) pre-XDR and 64/321 (19.93%) XDR-MTB. Overall, 303/400 (75.75%) LVX- and 292/400 (73.00%) MXF-resistant (R) MTB strains were identified. Two hundred seventy-one out of three hundred and three (89.43%) resistant strains carried mutations in gyrA and 91/303 (30.03%) in gyrB . Interestingly, 18 novel mutations were detected in gyrA and gyrB genes. Mutations at (A90, D94) and (T500, G510, G512) frequently existed in QRDR(s) of gyrA and gyrB respectively in 286/400 (71.50%) LVX R MXF R strains. The novel mutations in- and out-side the QRDR of gyrA (L105R, A126E, M127K, D151T, V165A) and gyrB (D461H, N499S, G520A) increased the sensitivity and consistency of genotypic tests. Notably, 25 LVX R MXF R strains were found with unknown resistance mechanisms. Conclusions: Mutations in QRDR(s) were concomitantly associated with Beijing and non-Beijing genotypes. The prevalence of resistance and cross-resistance between LVX and MXF in MTB isolates from southern China was immensely higher than other countries. Our valuable findings provide the substantial implications to improve the reliability of genotypic diagnostic tests relying on potential resistance conferring mutations in entire gyr genes.
机译:背景:Levofloxacin(LVX)和Moxifloxacin(MXF)是用于治疗多药抗性结核(MDR-TB)的基石。中国是MDR-和氟喹诺酮(FQ)抗性TB的最高的抗议者之一。由Gyr基因编码的DNA戊酶是结核分枝杆菌(MTB)中FQ的主要靶标。本研究检测了中国南部LVX和MXF耐药MTB菌株的患病率和分子表征。方法:通过对10种药物的LαWenstein-Jensen(LJ)培养基的比例方法评估400 MTB临床分离株的药物敏感性试验(DST)。进行整个Gyra和GyrB基因和多重PCR的测序,以区分北京和非北京基因型的突变类型的患病率。结果:四百(80.25%)耐药分离株(耐药>一种药物)三百二十一,分类为83/321(25.80%)MDR,174/321(54.20%)预先XDR和64 / 321(19.93%)XDR-MTB。总体而言,鉴定了303/400(75.75%)LVX-and 292/400(73.00%)MXF抗性(R)MTB菌株。三百七十一度三百七十一(89.43%)抗性菌株在Gyra和91/303(30.03%)中的突变在陀螺中。有趣的是,在Gyra和GyrB基因中检测到18种新突变。 (A90,D94)和(T500,G510,G512)的突变分别在286/400(71.50%)LVX R MXF R株中分别在Gyra和GyrB的QRDR中存在。基于和外侧的新型突变(L105R,A126E,M127K,D151T,V165A)和GyrB(D461H,N499S,G520A)的QRDR(L105R,A126E,M127K,D151,N499S)增加了基因型测试的敏感性和一致性。值得注意的是,发现25LVX R MXF R应菌株未知的电阻机制。结论:QRDR的突变伴随着与北京和非北京基因型相关。来自中国南部的MTB分离株中LVX和MXF之间的抗性和交叉抗性的患病率比其他国家更高。我们宝贵的发现提供了重大影响,提高基因型诊断试验的可靠性依赖于整个Gyt基因的潜在阻力突变。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号